Skip To Main Content
Benjamin Barwick on Muck Rack

Benjamin Barwick

Atlanta
As seen in: Nature, Science Magazine, BioRxiv, Cell Press, Genome Research, The Journal of Immunology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Benjamin

Contact Benjamin, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

KDM6A Regulates Immune Response Genes in Multiple Myeloma

|
By Daphné Dupéré-Richer, Alberto Riva Verified, Sayantan Maji, Benjamin Barwick
| BioRxiv
Abstract The histone H3K27 demethylase KDM6A is a tumor suppressor in multiple cancers, including multiple myeloma (MM). We created isogenic MM cells disrupted for KDM6A and tagged the endogenous protein to facilitate genome wide studies. KDM6A binds genes associated with immune recognition and cytokine signaling. Most importantly, KDM6A binds and activates NLRC5 and CIITA encoding regulators of Major Histocompatibility Complex (MHC) genes.
Open in Who Shared Issue with article?

Genome-scale functional genomics identify genes preferentially essential for multiple myeloma cells compared to other neoplasias - Nature Cancer

|
By Benjamin Barwick, Vikas Gupta, Yiguo Hu, Jordan G Bryan, Andrew J. Aguirre, Benjamin Ebert, Christopher J. Ott, James E. Bradner, Jonathan Keats, Nathanael S. Gray, Aedín C. Culhane, James M McFarland, Joshua M. Dempster, Jonathan D. Licht, Lawrence Boise, William Hahn, Francisca Vazquez, Aviad Tsherniak
| Nature Verified
Abstract Clinical progress in multiple myeloma (MM), an incurable plasma cell (PC) neoplasia, has been driven by therapies that have limited applications beyond MM/PC neoplasias and do not target specific oncogenic mutations in MM. Instead, these agents target pathways critical for PC biology yet largely dispensable for malignant or normal cells of most other lineages.
Open in Who Shared Issue with article?

Chromatin Accessibility Identifies Regulatory Elements Predictive of Gene Expression and Disease Outcome in Multiple Myeloma

|
By Benjamin Barwick, Vikas Gupta, Shannon M. Matulis, Jonathan Patton
| AACR Journal
Translational Cancer Mechanisms and Therapy Benjamin G. Barwick, Vikas A. Gupta, Shannon M. Matulis, Jonathan C. Patton, Doris R. Powell, Yanyan Gu, David L. Jaye, Karen N. Conneely, Yin C. Lin, Craig C. Hofmeister, Ajay K. Nooka, Jonathan J. Keats, Sagar Lonial, Paula M. Vertino and Lawrence H. Boise DOI: 10.1158/1078-0432.CCR-20-2931 Published June 2021 This article requires a subscription to view the full text.
Open in Who Shared Issue with article?
See all 16 articles